Merck & Co. (MRK) : United Capital Financial Advisers scooped up 24,789 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 11, 2016. The investment management firm now holds a total of 660,025 shares of Merck & Co. which is valued at $35.6 Million.Merck & Co. makes up approximately 0.39% of United Capital Financial Advisers’s portfolio.
Other Hedge Funds, Including , Canandaigua National Bank Trust Co boosted its stake in MRK in the latest quarter, The investment management firm added 2,858 additional shares and now holds a total of 70,942 shares of Merck & Co. which is valued at $3.8 Million. Merck & Co. makes up approx 1.14% of Canandaigua National Bank Trust Co’s portfolio.Staley Capital Advisers Inc reduced its stake in MRK by selling 300 shares or 5.21% in the most recent quarter. The Hedge Fund company now holds 5,454 shares of MRK which is valued at $292,334. Merck & Co. makes up approx 0.03% of Staley Capital Advisers Inc’s portfolio.Cypress Asset Management Inctx reduced its stake in MRK by selling 987 shares or 0.86% in the most recent quarter. The Hedge Fund company now holds 113,193 shares of MRK which is valued at $6.1 Million. Merck & Co. makes up approx 1.22% of Cypress Asset Management Inctx’s portfolio. Harfst Associates sold out all of its stake in MRK during the most recent quarter. The investment firm sold 28,964 shares of MRK which is valued $1.6 Million.Klingenstein Fields Co boosted its stake in MRK in the latest quarter, The investment management firm added 44,913 additional shares and now holds a total of 137,659 shares of Merck & Co. which is valued at $7.4 Million. Merck & Co. makes up approx 0.36% of Klingenstein Fields Co’s portfolio.
Merck & Co. opened for trading at $53.77 and hit $54.77 on the upside on Monday, eventually ending the session at $54.65, with a gain of 1.43% or 0.77 points. The heightened volatility saw the trading volume jump to 66,49,085 shares. Company has a market cap of $151,273 M.
On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.
Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.